|
Agents targeting DNA methylation and histone deacetylase in preclinical and clinical development |
| DNA methylation inhibitors |
|
|
| deoxycytidine analogs: |
| 5-azacytidine, 5-aza-2-deoxycytidine, 1-β-D-arabinofuranosil 5-azacytosine, dihydro- 5-azacytidine |
| nucleic acid-based: |
| MG98 antisense oligonucleotide |
| cytidine deaminase analogs: |
| zebularine |
| non-nucleoside analogs: |
| (-)-epigallocatechin-3-gallate, procaine, procainamide, hydralazine, RG108, psammaplins |
| Histone deacetylase inhibitors |
| Small molecular weight carboxilates: |
| sodium butyrate, valproic acid, sodium phenylbutyrate and pivaloyloxymethyl butyrate |
| Hydroxamic acids: |
| SAHA, trichostatin A, SBHA |
| Benzamides: |
| CI-994, MS-275 |
| Epoxyketones: |
| trapoxin B, 2-amino-8-oxo-9,10-epoxydecanoic acid |
| Cyclic peptides: |
| apicidin, depsipeptide |
| Hybrid molecules: |
| CHAP 31, CHAP50 |
| Miscellaneous: |
| Cyclostellettamines, Carbamazepine |
|
Adapted from reference 106. |
Arce et al. Journal of Translational Medicine 2006 4:10 doi:10.1186/1479-5876-4-10 |